Markets:

Overview

News

Currencies

International

Treasuries

Pfizer (NY:PFE)

28.28 +0.46 (+1.65%)

Official Closing Price Updated: 7:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 08, 2026

Both face patent cliffs and regulatory headwinds, but their balance sheets and cash generation tell starkly different stories.

Via The Motley Fool

Topics Intellectual Property

2 Growth Stocks to Buy in October ↗

October 08, 2026

Grail and Veeva Systems could be well insulated from near-term headwinds.

Via The Motley Fool

Pfizer Trades Under 10 Times Forward Earnings With a Yield Near 6%. Here's What History Says Happens Next. ↗

October 08, 2026

Pfizer is deeply unloved, and for good reason, but don't count this drug maker out just yet.

Via The Motley Fool

Topics Intellectual Property

Avident Health and Unite for HER Awarded Quality Improvement Grant from Pfizer and the National Comprehensive Cancer Network® (NCCN®) to Support Metastatic Breast Cancer Patients

October 08, 2026

October 8, 2026 -- Initiative leverages the MyNavigator™ digital care coordination platform to translate NCCN Guidelines® into actionable home-based education, expand access to integrative oncology...

Via 24-7 Press Release

Pfizer Stock: Buy, Sell, or Hold? ↗

October 07, 2026

The company is entering what could be a particularly challenging period.

Via The Motley Fool

Topics Intellectual Property

Pfizer’s TUKYSA Regimen Receives FDA Approval as Front-Line Maintenance Treatment for HER2+ Metastatic Breast Cancer

October 07, 2026

From Pfizer Inc.

Via Business Wire

D-Wave Quantum vs. Rigetti Computing: Which Cutting Edge Quantum Stock Is a Better Buy in 2026? ↗

October 07, 2026

D-Wave is growing revenue at nearly 180% while Rigetti trades at a lower valuation, but both burn cash heavily and face unproven commercial roadmaps.

Via The Motley Fool

Topics Supply Chain

Warren Buffett's Favorite Valuation Indicator Blew Past the Level He Warned Was "Playing With Fire." Here Are 3 Stocks Still Cheap Enough to Buy. ↗

October 07, 2026

Buffett thinks many stocks are too hot to touch right now, but these three aren't.

Via The Motley Fool

Topics Artificial Intelligence Energy

1 Healthcare Stock with Competitive Advantages and 2 We Find Risky

October 07, 2026

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva...

Via StockStory

3 of the Best Dividend Stocks to Buy in October 2026 ↗

October 06, 2026

A couple of the stocks on this list pay more than 6% in dividends.

Via The Motley Fool

Topics Economy Intellectual Property

Pfizer Declares Fourth-Quarter 2026 Dividend

October 06, 2026

From Pfizer Inc.

Via Business Wire

October 06, 2026

Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t...

Via StockStory

Eli Lilly Has Been a Growth Beast, but This Is the Riskiest Part About Its Stock ↗

October 05, 2026

The healthcare stock's elevated valuation bakes in high expectations, leaving little room for error.

Via The Motley Fool

Why Pfizer Might Be the Most Underrated Dividend Stock to Buy Right Now ↗

October 05, 2026

Many dividend investors may be overlooking Pfizer's stock, and that could be a costly mistake.

Via The Motley Fool

Topics Intellectual Property

Vaxcyte Catapults After Going Toe-To-Toe With Pfizer, Merck In Vaccine Study ↗

October 05, 2026

Vaxcyte stock catapulted Monday after its pneumococcal vaccine proved it's not inferior to shots from Pfizer and Merck.

Via Investor's Business Daily

Eli Lilly vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 05, 2026

Eli Lilly is dominating the GLP-1 market with nearly 50% revenue growth and a newly approved oral obesity pill. Pfizer is rebuilding its pipeline with obesity drug ambitions and a committed dividend...

Via The Motley Fool

Topics Intellectual Property

Got $10,000 to Invest in October? These Stocks Could Generate Over $634 in Annual Income. ↗

October 05, 2026

Put your money to work generating dividend income with these stocks.

Via The Motley Fool

Better High-Yield Dividend Stock: Pfizer or Novo Nordisk? ↗

October 04, 2026

Novo Nordisk covers its dividend, and Pfizer doesn't, but investors appear increasingly worried about Novo's future.

Via The Motley Fool

Here's Exactly Why I'm Not Afraid of Pfizer's 6% Dividend Yield ↗

October 04, 2026

The crowd is looking at the next couple of years. It should be looking five years into the future.

Via The Motley Fool

Topics Intellectual Property

3 Dirt Cheap Dividend Stocks Worth Buying in October ↗

October 04, 2026

There are blazing deals for some of the top healthcare stocks -- companies with proven track records and dividend yields as high as 6%.

Via The Motley Fool

Topics Intellectual Property

My 3 Favorite Ultra-High-Yield Dividend Stocks to Buy for October ↗

October 04, 2026

These stocks offer juicy yields and attractive risk-reward profiles.

Via The Motley Fool

Topics Artificial Intelligence Economy Energy

3 Income Stocks Under $30 That Yield More Than the 10-Year Treasury Note ↗

October 03, 2026

With the 10-year Treasury yielding around 5.3%, Pfizer, Energy Transfer, and Plains All American offer stocks under $30 with dividend yields between 6% and 7%.

Via MarketBeat

Topics Bonds Retirement

Bristol Myers Squibb Now Trades at Only 9.4X Forward Earnings -- Is This Value Stock a Buy? ↗

October 03, 2026

Bristol Myers Squibb isn't a growth stock, but it may offer something to bargain hunters and dividend seekers.

Via The Motley Fool

Topics Intellectual Property

Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP ↗

October 02, 2026

VanEck offers lower costs and double the dividend yield, while Invesco delivered stronger 1-year returns with more balanced holdings.

Via The Motley Fool

Topics ETFs

Novo Nordisk vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 02, 2026

Novo Nordisk boasts a 33% net margin and fortress balance sheet, while Pfizer trades cheaper but faces major patent cliffs through 2030.

Via The Motley Fool

Topics Intellectual Property

Pfizer’s LITFULO Significantly Improved Facial and Total Body Repigmentation in Patients with Nonsegmental Vitiligo

October 02, 2026

From Pfizer Inc

Via Business Wire

Pfizer Is Down 34% Over the Last 5 Years. Here's Why Its 6% Dividend Yield Might Finally Be Worth the Risk. ↗

October 02, 2026

Pfizer has been going through a period of transition.

Via The Motley Fool

Topics Earnings

Kevin Warsh's Inflation Stance Makes These Cheap Dividend Stocks Look a Lot More Attractive ↗

October 01, 2026

Inflation is running hot, and the Fed is raising interest rates, but consumers aren't likely to pull back on the products these companies sell.

Via The Motley Fool

Topics Economy

Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗

October 01, 2026

Regeneron Pharmaceuticals (NASDAQ:REGN) and Sanofi said they are expanding their long-running collaboration to develop and commercialize next-generation medicines for type 2 inflammatory diseases,...

Via MarketBeat

Topics ETFs

Pfizer's Tilrekimig Shows Significant Skin Clearance in Phase 2 Atopic Dermatitis Study

October 01, 2026

From Pfizer Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Pfizer (NY:PFE)

All News about Pfizer

Starting at /week.